RATIONALE: Dysfunction of glutamatergic neurotransmission has been implicated in the pathophysiology of obsessive-compulsive disorder (OCD) and recent clinical reports suggest that some glutamate modulating agents are efficacious in the treatment of this disorder. N-acetylcysteine (NAC) is a readily available amino acid compound that is thought to attenuate glutamatergic neurotransmission. NAC may be useful in treating psychiatric disorders involving glutamatergic dysfunction such as OCD. OBJECTIVES: To examine the efficacy of augmentation with NAC in a patient with serotonin reuptake inhibitor (SRI)-refractory OCD. METHODS: A patient with SRI-refractory OCD was treated with an off-label use of NAC augmentation of fluvoxamine over several weeks. RESULTS: NAC augmentation of fluvoxamine resulted in a marked decrease in Yale-Brown Obsessive Compulsive Scale (Y-BBOCS) score and a clinically significant improvement in OCD symptoms. CONCLUSIONS: NAC augmentation was effective in treating SRI-refractory OCD in this single case. Further research is warranted to investigate the use of NAC and other glutamate modulating agents in the treatment of OCD.
RATIONALE: Dysfunction of glutamatergic neurotransmission has been implicated in the pathophysiology of obsessive-compulsive disorder (OCD) and recent clinical reports suggest that some glutamate modulating agents are efficacious in the treatment of this disorder. N-acetylcysteine (NAC) is a readily available amino acid compound that is thought to attenuate glutamatergic neurotransmission. NAC may be useful in treating psychiatric disorders involving glutamatergic dysfunction such as OCD. OBJECTIVES: To examine the efficacy of augmentation with NAC in a patient with serotonin reuptake inhibitor (SRI)-refractory OCD. METHODS: A patient with SRI-refractory OCD was treated with an off-label use of NAC augmentation of fluvoxamine over several weeks. RESULTS:NAC augmentation of fluvoxamine resulted in a marked decrease in Yale-Brown Obsessive Compulsive Scale (Y-BBOCS) score and a clinically significant improvement in OCD symptoms. CONCLUSIONS:NAC augmentation was effective in treating SRI-refractory OCD in this single case. Further research is warranted to investigate the use of NAC and other glutamate modulating agents in the treatment of OCD.
Authors: David A Baker; Krista McFarland; Russell W Lake; Hui Shen; Xing-Chun Tang; Shigenobu Toda; Peter W Kalivas Journal: Nat Neurosci Date: 2003-07 Impact factor: 24.884
Authors: Vladimir Coric; Sarper Taskiran; Christopher Pittenger; Suzanne Wasylink; Daniel H Mathalon; Gerald Valentine; John Saksa; Yu-Te Wu; Ralitza Gueorguieva; Gerard Sanacora; Robert T Malison; John H Krystal Journal: Biol Psychiatry Date: 2005-09-01 Impact factor: 13.382
Authors: David Mataix-Cols; Scott L Rauch; Lee Baer; Jane L Eisen; David M Shera; Wayne K Goodman; Steven A Rasmussen; Michael A Jenike Journal: Am J Psychiatry Date: 2002-02 Impact factor: 18.112
Authors: Megan M Moran; Krista McFarland; Roberto I Melendez; Peter W Kalivas; Jeremy K Seamans Journal: J Neurosci Date: 2005-07-06 Impact factor: 6.167
Authors: Benjamin D Greenberg; Lawrence H Price; Scott L Rauch; Gerhard Friehs; Georg Noren; Donald Malone; Linda L Carpenter; Ali R Rezai; Steven A Rasmussen Journal: Neurosurg Clin N Am Date: 2003-04 Impact factor: 2.509
Authors: Carolyn I Rodriguez; James Bender; Sue M Marcus; Michael Snape; Moira Rynn; Helen Blair Simpson Journal: J Clin Psychiatry Date: 2010-09 Impact factor: 4.384
Authors: Giselli Scaini; Gabriela C Jeremias; Camila B Furlanetto; Diogo Dominguini; Clarissa M Comim; João Quevedo; Patrícia F Schuck; Gustavo C Ferreira; Emilio L Streck Journal: JIMD Rep Date: 2013-11-09
Authors: Michael H Bloch; Christy Green; Stephen A Kichuk; Philip A Dombrowski; Suzanne Wasylink; Eileen Billingslea; Angeli Landeros-Weisenberger; Benjamin Kelmendi; Wayne K Goodman; James F Leckman; Vladimir Coric; Christopher Pittenger Journal: Depress Anxiety Date: 2013-03-26 Impact factor: 6.505